Treatment of paranasal sinus malignancy: the BCCA experience.
A retrospective analysis was undertaken of 119 patients treated at the British Columbia Cancer Agency (BCCA) with a diagnosis of paranasal sinus malignancy. All patients from 1970 to 1987 were included in the review. A comparison is drawn between main treatment modalities, namely primary radiotherapy, primary surgical resection and combined therapy. Clinical characteristics of this relatively rare lesion are elucidated. Recommendations regarding optimal therapy are made on the basis of this data.
MacNab
T I
TI
Department of Surgery, University of British Columbia, Vancouver, Canada.
Flores
A D
AD
Anderson
D W
DW
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001955:British Columbia / Q000453:epidemiology; D002173:Cancer Care Facilities; D002985:Clinical Protocols / Q000592:standards; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D010255:Paranasal Sinus Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000601:surgery*; D011379:Prognosis; D011878:Radiotherapy / Q000592:standards*; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome